Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Ge, T.S.; Shen, Qiujin; Wang, Ning; Zhang, Yurong; Ge, Zhouhong; Chu, Wei; Lv, Xiufang; Zhao, Fengbo; Zhao, Weifeng; Fan, Jia; Qin, Wenxin

doi:10.1007/s12032-014-0367-z

Cited by 56 publications

(64 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, serum DKK-1 level was significantly higher in HCC patients than those of cirrhotic and healthy groups, while there was no significant difference in DKK1 levels between cirrhotic and control groups. This was in accordance with what was stated by many authors (16)(17)(18)(19)(20) ; as they found that DKK1 levels were significantly higher in HCC and could distinguish HCC patients from cirrhotic patients and from healthy controls.…”

Section: Discussion:-supporting

confidence: 93%

Assessment of Dickkopf-1 as a Biomarker of Hepatocellular Carcinoma in Egyptians.

AtefSharaki¹,

ElSayedZeid²,

NazeihYounan³

et al. 2019

IJAR

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is considered to be one of the most aggressive malignancies. Several studies have shown that dickkopf-1 (DKK1) is overexpressed in HCC tissue. Objective and Methods: The present study aimed at demonstrating the diagnostic efficacy of serum levels of DKK1 in HCC in comparison to alpha fetoprotein (AFP). Eighty individuals were included in the present study, and categorized to three groups: Group I: 40 patients with HCC on top of viral liver cirrhosis, Group II: 20 patients with viral induced liver cirrhosis without HCC, and Group III: 20 healthy individuals. Serum levels of AFP and DKK1 were measured and compared in all groups. Results: The values of AFP and DKK1 in group I were statistically higher than those in groups II and III. At the optimum value of 11.7 ng/ml, the sensitivity and specificity of serum AFP were 70.0% and 87.5%, respectively. DKK1 had higher sensitivity (80.0%) and specificity (90.0%) than AFP, at the cut-off value of 1.28 ng/ml for the diagnosis of HCC. Area under the curve (AUC) was higher in DKK1 (0.811) than AFP (0.779) when discriminating between group I and other groups. It was noted that the combination of both markers had a higher sensitivity and specificity, and a larger AUC than each alone. Conclusion: Serum DKK1 is a promising biomarker and is superior to AFP for HCC diagnosis. Combination of AFP and DKK1 improved the accuracy of HCC diagnosis in relation to each test alone.

show abstract

Section: Discussion:-supporting

confidence: 93%

Assessment of Dickkopf-1 as a Biomarker of Hepatocellular Carcinoma in Egyptians.

AtefSharaki¹,

ElSayedZeid²,

NazeihYounan³

et al. 2019

IJAR

View full text Add to dashboard Cite

show abstract

“…Furthermore, we showed that the performance of OPN remained intact a year prior to HCC diagnosis in this high risk group (8, 9). The performance of OPN for the early detection of HCC was further validated in independent studies (10–12). OPN is an extracellular matrix protein that has been implicated in several carcinogenic and angiogenic processes, such as cell invasion, inflammation, tumor progression, and metastasis (13, 14).…”

Section: Introductionmentioning

confidence: 96%

Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

Duarte‐Salles

Misra

Stępień

et al. 2016

Cancer Prevention Research

View full text Add to dashboard Cite

We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between pre-diagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested-case control study was conducted within the EPIC cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function and alpha-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95%CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable=1.30; 95%CI:1.14–1.48). The association was stronger among cases diagnosed within two years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC=0.86). For cases diagnosed within two years, the combination of OPN and AFP was best able to predict HCC risk (AUC=0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within two years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis.

show abstract

“…Also, the sensitivity and specificity of our model are higher than that of other HCC markers like for AFP, they were 61 and 71 %; for DCP, 39 and 90 %; for AFP-L3, 37 and 92 %; for dickkopf-1 (DKK1), 69.1 and 90.6; and for osteopontin (OPN), 74 and 66 %, respectively. Also, our outcomes are superior to that of AFP and AFP-L3 combination, 77 % sensitivity; AFP and DCP combination, 59 % sensitivity; and AFP, DKK1 and OPN combination, 88.76 % [6,[33][34][35][36]. Moreover, the GPC-HCC model has higher sensitivity than do other GPC3 and AFP combinations.…”

Section: Discussionmentioning

confidence: 79%

GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Conflicting results for circulating glypican-3 (GPC3) were reported in hepatocellular carcinoma (HCC) diagnosis. We aimed to improve the diagnostic power of GPC3 by developing a GPC-HCC model for diagnosing HCC. GPC3 was tested for HCC (138), liver cirrhosis (56), and fibrosis (62) patients by ELISA. Data from patient groups were retrospectively analyzed. A novel score, GPC-HCC, based on combination of GPC3 and routine laboratory tests, was developed for HCC diagnosis. The GPC-HCC model values produced a significant 1.7-fold increase in liver cirrhosis and 3.2-fold increase in HCC, in comparison with liver fibrosis. In contrast to GPC3 and alpha fetoprotein (AFP), the GPC-HCC model showed high HCC diagnostic power with area under the curve (AUC) of 0.939, sensitivity 93 %, specificity 93 %, positive predictive value 89 %, negative predictive value 95 %, and efficiency 93 %. GPC-HCC AUC in HCC with single tumor, absent vascular invasion, and tumor size ≤3 cm were 0.93, 0.92, and 0.92, respectively, compared with 0.63, 0.63, and 0.64, respectively, for GPC3 and 0.69, 0.70, 0.55, respectively, for AFP. In conclusion, owing to these promising findings, the combination of GPC3 with other laboratory simple routine tests (GPC-HCC model) could improve the diagnostic power of GPC3 in HCC screening and follow up of cirrhotic patients.

show abstract

Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma

Cited by 56 publications

References 39 publications

Assessment of Dickkopf-1 as a Biomarker of Hepatocellular Carcinoma in Egyptians.

Assessment of Dickkopf-1 as a Biomarker of Hepatocellular Carcinoma in Egyptians.

Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population

GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma

Contact Info

Product

Resources

About